Mohini Varughese

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquı́n Mateo, Núria Porta, Diletta Bianchini et al. · The Lancet Oncology · 2019 · 632 citations · Full text

Genomics of lethal prostate cancer at diagnosis and castration resistance

Joaquı́n Mateo, George Seed, Cláudia Bertan et al. · Journal of Clinical Investigation · 2019 · 292 citations · Full text

Urology, Oncology, Genomic Aberrations +13

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes

James W.F. Catto, Amy Downing, Samantha J. Mason et al. · European Urology · 2021 · 152 citations · Full text

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 111 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +7